Discussion about this post

User's avatar
TT's avatar

Thanks for the update. The combination of drop in Epuris and increase of cash as a percentage of the market cap make me nervous. This is now almost entirely a story about what management is going to buy with their overcapitalized balance sheet

Expand full comment
Benji's avatar

Almost a year ago I was going back and forth between Cipher and Medexus... I feel in love with treosulfan and went with Medexus. My first “well that was stupid” mistake. Definitely looks good if they can find good places for that cash.

Expand full comment
5 more comments...

No posts